Merck Says FDA Approves Keytruda, Keytruda Qlex With Padcev For Perioperative Treatment Of MIBC
MRK•FDA approves perioperative bladder cancer treatment
- FDA approves Keytruda (pembrolizumab) and Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph), each with Padcev (enfortumab vedotin-ejfv), as treatment before and after surgery for adults with muscle-invasive bladder cancer (MIBC).
Related News
Zoom Communications, Inc. <ZM.O>: Jefferies cuts target price to $116 from $118
ZM•
MongoDB, Inc. <MDB.O>: Barclays Raises Target Price to $460 From $387
MDB•
